Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 583-584 , November 2009

Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer

References 

  1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  2. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  3. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  4. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521–1527
  5. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  6. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol. 2007;178:2359–2364Discussion 2364–5
  7. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004;171:2239–2244

PII: S1078-1439(09)00193-8

doi: 10.1016/j.urolonc.2009.06.011

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 6 , Pages 583-584 , November 2009

Article Tools